Physicians at the University of Oklahoma Health Sciences Center in Oklahoma City are spearheading a groundbreaking national clinical trial aimed at helping women with infertility caused by polycystic ovary syndrome (PCOS).
The trial, known as REBALANCE, evaluates the safety and efficacy of an innovative device created by May Health, designed to restore ovulation in women whose reproductive cycles are disrupted by PCOS. Dr. Karl Hansen, M.D., Ph.D., a reproductive endocrinologist and chair of the Department of Obstetrics and Gynecology at the OU College of Medicine, is leading the study at OU Health. Notably, Dr. Hansen was the first physician in the United States to utilize the device in clinical practice.
PCOS is a widespread endocrine disorder that affects approximately 10% of women of reproductive age, making it the leading cause of infertility due to the absence of ovulation. The REBALANCE trial offers hope by investigating new avenues of treatment for this challenging condition.
In discussing the significance of the trial, Dr. Hansen emphasized the role of academic medicine in advancing patient care. “Our goal is not only to provide the treatments we already know work but to push the boundaries of medical knowledge and innovation,” he said.
This pioneering trial could pave the way for new options in the management of PCOS-related infertility, offering new possibilities for women seeking to start a family.
Related topics:
Mumbai’s Cama Hospital Introduces PRP Therapy to Boost Ovarian Reserve in Infertility Treatment
